Sharon Barrans
Overview
Explore the profile of Sharon Barrans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang C, Stelloo E, Barrans S, Cucco F, Jiang D, Tzioni M, et al.
Leukemia
. 2024 Jan;
38(3):621-629.
PMID: 38184753
MYC translocation occurs in 8-14% of diffuse large B-cell lymphoma (DLBCL), and may concur with BCL2 and/or BCL6 translocation, known as double-hit (DH) or triple-hit (TH). DLBCL-MYC/BCL2-DH/TH are largely germinal...
2.
Lamb M, Painter D, Howell D, Barrans S, Cargo C, de Tute R, et al.
Cancer Epidemiol
. 2023 Dec;
88:102513.
PMID: 38160571
Background: Population-based information on cancer incidence and outcome are required to inform clinical practice and research; but contemporary data are lacking for many lymphoid cancer subtypes. Methods: Set within a...
3.
Davies J, Hilton L, Jiang A, Barrans S, Burton C, Johnson P, et al.
Blood Adv
. 2023 Aug;
7(20):6156-6162.
PMID: 37595057
No abstract available.
4.
Davies A, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al.
J Clin Oncol
. 2023 Mar;
41(15):2718-2723.
PMID: 36972491
JCO The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by...
5.
Bewicke-Copley F, Korfi K, Araf S, Hodkinson B, Kumar E, Cummin T, et al.
Blood Adv
. 2022 Aug;
7(5):845-855.
PMID: 35947123
Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse...
6.
Phillips E, Burton C, Kirkwood A, Barrans S, Lawrie A, Rule S, et al.
EJHaem
. 2022 Jul;
1(1):133-141.
PMID: 35847742
Introduction: Outcomes after frontline treatment of Burkitt lymphoma (BL) have improved with the introduction of dose-intense chemotherapy regimens, such as CODOX-M/IVAC. While rituximab has increased survival rates for most forms...
7.
Kizhakeyil A, Zaini N, Poh Z, Wong B, Loh X, Ng A, et al.
Mol Cancer
. 2021 Oct;
20(1):134.
PMID: 34654425
No abstract available.
8.
Gong C, Krupka J, Gao J, Grigoropoulos N, Giotopoulos G, Asby R, et al.
Mol Cell
. 2021 Aug;
81(19):4059-4075.e11.
PMID: 34437837
DDX3X is a ubiquitously expressed RNA helicase involved in multiple stages of RNA biogenesis. DDX3X is frequently mutated in Burkitt lymphoma, but the functional basis for this is unknown. Here,...
9.
Davies A, Barrans S, Burton C, Mercer K, Caddy J, Chinnery F, et al.
F1000Res
. 2020 Oct;
9:941.
PMID: 33093947
Over 13,000 new cases of non-Hodgkin's lymphoma (NHL) are diagnosed in the UK, with approximately 4,900 attributable deaths each year. Diffuse Large B-cell Lymphoma (DLBCL) is the most common NHL...
10.
Runge H, Lacy S, Barrans S, Beer P, Painter D, Smith A, et al.
Br J Haematol
. 2020 Oct;
192(1):216-220.
PMID: 33010029
No abstract available.